Clinical Trials Browser

INDUSTRY × Interventional × ALK or ROS1-positive NSCLC × Clear all

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Phase 4 Terminated

41 enrolled 9 charts

ALK or ROS1-positive NSCLC